Equities researchers at StockNews.com began coverage on shares of Second Sight Medical Products (NASDAQ:EYES – Get Rating) in a research note issued to investors on Monday. The firm set a "sell" rating on the medical device company's stock.

Second Sight Medical Products Price Performance

Second Sight Medical Products stock opened at $4.14 on Monday. Second Sight Medical Products has a fifty-two week low of $3.42 and a fifty-two week high of $12.72. The stock's fifty day moving average is $5.71 and its two-hundred day moving average is $5.21.

Institutional Trading of Second Sight Medical Products

Several large investors have recently bought and sold shares of the company. Jane Street Group LLC boosted its stake in shares of Second Sight Medical Products by 111.8% during the second quarter. Jane Street Group LLC now owns 21,601 shares of the medical device company's stock valued at $44,000 after acquiring an additional 11,403 shares during the last quarter. Virtu Financial LLC boosted its stake in shares of Second Sight Medical Products by 130.6% during the second quarter. Virtu Financial LLC now owns 31,258 shares of the medical device company's stock valued at $63,000 after acquiring an additional 17,703 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Second Sight Medical Products during the second quarter valued at $207,000. Renaissance Technologies LLC acquired a new stake in shares of Second Sight Medical Products during the first quarter valued at $249,000. Finally, Vanguard Group Inc. boosted its stake in shares of Second Sight Medical Products by 1.4% during the first quarter. Vanguard Group Inc. now owns 1,221,704 shares of the medical device company's stock valued at $1,747,000 after acquiring an additional 17,164 shares during the last quarter.

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury.

See Also

• Get a free copy of the StockNews.com research report on Second Sight Medical Products (EYES)
• Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
• Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
• Magna International is Your Auto and EV One-Stop Shop Stock
• EV Battery Maker Freyr Set For Major Global Expansion
• MarketBeat: Week in Review 9/26 – 9/30

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.